Diffuse melanosis cutis: a rare manifestation of metastatic melanoma.


Journal

BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291

Informations de publication

Date de publication:
30 Aug 2019
Historique:
entrez: 2 9 2019
pubmed: 2 9 2019
medline: 7 2 2020
Statut: epublish

Résumé

Diffuse melanosis cutis (DMC) is an extremely rare and late complication of metastatic melanoma (MM). It involves the progressive blue-grey discolouration of the skin and mucous membranes, occurring approximately 1 year after diagnosis of MM. The pathogenesis of DMC is unknown, although specific growth factors, such as alpha-melanocyte stimulating hormone, hepatocyte growth factor and endothelin-1, released by cancer cells, along with release of melanin precursors in the bloodstream and dermal MM micrometastases producing melanin have been attributed. Even with appropriate therapy, DMC seems to be a poor prognostic factor, with a mean survival time of 4-5 months. Here, we report a case of BRAF-mutated MM who presented with DMC. The patient underwent BRAF/MEK inhibition followed by anti-PDL1 therapy, yet passed away approximately 1 year after diagnosis.

Identifiants

pubmed: 31473636
pii: 12/8/e230396
doi: 10.1136/bcr-2019-230396
pmc: PMC6720706
pii:
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Int J Dermatol. 2014 Nov;53(11):1409-11
pubmed: 25257244
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
J Dtsch Dermatol Ges. 2012 Oct;10(10):764-5
pubmed: 22759393
Am J Surg. 1978 Jun;135(6):807-10
pubmed: 665907
Br J Surg. 1961 Mar;48:549-55
pubmed: 13706990
Lancet Oncol. 2016 Sep;17(9):1248-60
pubmed: 27480103
Australas J Dermatol. 2015 May;56(2):128-30
pubmed: 25159853
Cancers (Basel). 2010 Dec 30;3(1):126-63
pubmed: 24212610
Semin Oncol. 2016 Jun;43(3):384-9
pubmed: 27178692
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494
J Am Acad Dermatol. 2013 Mar;68(3):482-8
pubmed: 23219556
J Am Acad Dermatol. 2001 May;44(5):747-54
pubmed: 11312419
Eur J Cancer. 2016 Jul;62:132-7
pubmed: 27189322
Medicine (Baltimore). 2017 Apr;96(15):e6470
pubmed: 28403076

Auteurs

Brian Chinai (B)

Cooper University Hospital, Camden, New Jersey, USA.

Michael Piazza (M)

Cooper University Hospital, Camden, New Jersey, USA.

Ritesh Patel (R)

Cooper University Hospital, Camden, New Jersey, USA.

Satyajeet Roy (S)

Internal Medicine, Cooper University Hospital, Cherry Hill, New Jersey, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH